Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2009

View Archived Issues

HSP 90 and kinase inhibitors presented by the University of Strasbourg

Novel TRPV1 receptor antagonists claimed by Renovis and Pfizer

C5aR antagonist shows promise in murine models of Alzheimer's disease

P2X7 receptor blockade improves functional recovery after SCI

Carisbamate suppresses alcohol intake in rat model of alcoholism

Johnson & Johnson develops DGAT1 inhibitors for treating the metabolic syndrome

Gefitinib derivatives in development at Concert Pharmaceuticals

Ustav Organicke Chemie a Biochemie discloses novel apoptosis inhibitors

PharmacoFore introduces novel anesthetics

Natco Pharma claims novel HER (erbB) tyrosine kinase and VEGFR inhibitors

Alpha2B- and alpha2C-adrenoceptor agonists identified at Allergan

Vertex reports results from second quarter 2009

Protalix receives FDA fast track designation for prGCD for Gaucher's disease

BioAlliance presents preliminary pivotal phase III results with acyclovir Lauriad

Lurasidone demonstrates efficacy in schizophrenia

Acorda reports FDA Advisory Committee review date for Fampridine-SR

FDA accepts Labopharm's resubmission response for novel trazodone hydrochloride formulation

Hawaii Biotech initiates phase I clinical trial for dengue vaccine

ISTA reports preliminary phase III results for once-daily Xibrom 0.09%

Morria obtains clearance to conduct phase II MRX-6 study for contact dermatitis

Adolor introduces novel cannabinoid CB2 receptor ligands as analgesics

Profectus enters research collaboration with the PATH Malaria Vaccine Initiative

Taisho and Nissan discontinue development of NT-702 for spinal canal stenosis

NovaBiotics completes phase I clinical study of Novexatin for onychomycosis

Novel antiplatelet agents presented by Astellas as potential clinical candidates

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.